Abstract
The aim of the study was to evaluate the results of treatment of 46 children with non B non-Hodgkin's Lymphoma registered in 7 centers of Polish Paediatric Leukaemia/Lymphoma Study Group from 1993 to 1998. The patients were treated according to BFM-90 protocol based on German regimen. The overall probability of event-free survival for the all children after 4 years of follow-up was 71%, for patients in stage III--65%, stage IV--70%. The achieved results were not as positive as in the BFM Study Group, what was related to: the great number of children with advanced stage of disease (54.3%), the late final diagnosis, the great number of recurrences (22.5%) and deaths caused by the toxicity of medication (6.5%) (infections, drug toxicity).
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Asparaginase / administration & dosage
-
Child
-
Child, Preschool
-
Cyclophosphamide / administration & dosage
-
Cytarabine / administration & dosage
-
Daunorubicin / administration & dosage
-
Female
-
Follow-Up Studies
-
Humans
-
Infant
-
Lymphoma, Non-Hodgkin / drug therapy*
-
Lymphoma, Non-Hodgkin / mortality
-
Male
-
Mercaptopurine / administration & dosage
-
Methotrexate / administration & dosage
-
Neoplasm Staging
-
Poland
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
-
Prednisone / administration & dosage
-
Retrospective Studies
-
Survival Rate
-
Treatment Failure
-
Vincristine / administration & dosage
Substances
-
Cytarabine
-
Vincristine
-
Cyclophosphamide
-
Mercaptopurine
-
Asparaginase
-
Prednisone
-
Methotrexate
-
Daunorubicin
Supplementary concepts
-
AIEOP acute lymphoblastic leukemia protocol